2.64
Gain Therapeutics Inc Stock (GANX) Latest News
Gain Therapeutics Advances GT-02287 in Parkinson’s Trials - TipRanks
Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update - citybiz
Travere Therapeutics Inc (TVTX) deserves deeper analysis - US Post News
Are Corcept Therapeutics Inc’shares a good deal? - US Post News
Parkinson's Breakthrough: New Drug Shows 53% Enzyme Boost, Phase 1b Trial Launching - StockTitan
Spero Therapeutics Inc (SPRO)’s results reveal risk - US Post News
Gain Therapeutics (NASDAQ:GANX) Shares Up 10.4% – What’s Next? - Defense World
Viridian Therapeutics Inc (VRDN)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Market Insights: Avidity Biosciences Inc (RNA)’s Notable Gain of 4.32, Closing at 33.34 - The Dwinnex
Gain Therapeutics To Participate in Upcoming Investor Conferences - The Manila Times
Gain Therapeutics, Inc. Announces Upcoming Presentations at BIO CEO & Investor Conference and Oppenheimer 35th Annual Healthcare Life Sciences Conference - Nasdaq
Biotech Spotlight: Gain Therapeutics Takes Center Stage at Two Major Investor Conferences - StockTitan
Have you been able to find a good deal on Capricor Therapeutics Inc’s shares? - US Post News
Closing Figures Unveiled: Canada Goose Holdings Inc (GOOS) Gain 1.05, Closes at 10.57 - The Dwinnex
4D Molecular Therapeutics Inc (FDMT) deserves deeper analysis - US Post News
Are Stoke Therapeutics Inc (STOK) shares a good deal now? - US Post News
Spyre Therapeutics Inc (SYRE) stock analysis: A comprehensive overview - US Post News
Should investors be concerned about Unicycive Therapeutics Inc (UNCY)? - US Post News
Is Tenaya Therapeutics Inc (TNYA) a good investment opportunity? - US Post News
Closing Figures Unveiled: Ondas Holdings Inc (ONDS) Gain 3.55, Closes at 1.75 - The Dwinnex
Stock summary: Cyclerion Therapeutics surged by 41.01% over the past five days - Business Upturn
Amentum Holdings Inc (AMTM) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Investors in Beam Therapeutics (NASDAQ:BEAM) from three years ago are still down 55%, even after 3.8% gain this past week - Yahoo Finance
Takeda makes waves again with CEO pick - BioCentury
UiPath Inc (PATH) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Medicare Advantage Members Gain Access to Innovative Digital Therapeutics Through New Partnership - Yahoo Finance
Sector Update: Health Care Stocks Gain Late Afternoon -January 27, 2025 at 04:04 pm EST - Marketscreener.com
Nvidia Shares Tumbles as Japanese Rivals Gain Ground in AI Chips - Yahoo Finance
This Weight-Loss Drug Stock Could Gain 200%, Challenge Novo Nordisk, Eli Lilly. - Barron's
Investors in Seres Therapeutics (NASDAQ:MCRB) from three years ago are still down 88%, even after 17% gain this past week - Simply Wall St
Vir, Sana gain new modality POC: BioCentury’s Clinical Report - BioCentury
Improved Revenues Required Before Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock's 30% Jump Looks Justified - Simply Wall St
Will CRL Stock Gain From Integration of Akron Bio's CSS Product Line? - Yahoo Finance
Perrigo cut to Hold at Argus on topline risks - MSN
Regions Financial Q4 2024 Earnings Preview - MSN
All You Need to Know About Gain Therapeutics (GANX) Rating Upgrade to Strong Buy - MSN
Gain Therapeutics regains compliance with Nasdaq listing By Investing.com - Investing.com South Africa
Gain Therapeutics regains compliance with Nasdaq listing - Investing.com India
Parkinson's Disease Clinical and Non-Clinical Studies, Key - openPR
Stock market today: Eterna Therapeutics gain over 136.63% while Phio Pharmaceuticals plunged by 40.25% in early trading - Business Upturn
Geode Capital Management LLC Has $484,000 Stock Holdings in Gain Therapeutics, Inc. (NASDAQ:GANX) - Defense World
Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews
Coinbase Global Inc (COIN) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Best Momentum Stocks to Buy for January 9th - Yahoo Finance
Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287 - The Manila Times
Gain Therapeutics Forms Elite Advisory Board to Accelerate Parkinson's Drug Development - StockTitan
Gain Therapeutics (GANX) Shares Rise In After-Hour Trading - Stocks Telegraph
Gain Therapeutics Appoints New CEO Amidst Clinical Progress - TipRanks
Gain Therapeutics Appoints Gene Mack as Chief Executive Officer - Marketscreener.com
Gain Therapeutics appoints new CEO and finance SVP - Investing.com
Gain Therapeutics Appoints Gene Mack as CEO - citybiz
Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director - The Manila Times
Gain Therapeutics Names Gene Mack as CEO, Advancing Parkinson's Disease Drug Development - StockTitan
Viking Therapeutics, Inc. (VKTX) Stock Sinks As Market Gains: What You Should Know - MSN
Drug Innovator Launches Pivotal Cancer Trial Breakthrough - Streetwise Reports
Miami Biopharma Sells Part of Business & Begins New Clinical Trial - Streetwise Reports
Tarsus PharmaceuticalEye Care Therapeutics - TradingView
Gold just saw its biggest yearly gain since 2010 — here's why Wall Street says prices will go even higher - Yahoo Finance
Analyst Sees Major Growth for Biopharma With Weight-Loss Drug - Streetwise Reports
Gain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good Results - Seeking Alpha
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):